MedTrace Logo

Acupuncture and Moxibustion for Hyperlipemia

NCT02269046 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2014-10-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of 12 weeks of acupuncture and moxibustion compared with active control, on absolute and percent change from baseline in low-density lipoprotein cholesterol (LDL-C) among those with hyperlipidemia.

Conditions

  • Hyperlipidemias

Interventions

OTHER

acupuncture and moxibustion

Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)

DRUG

Simvastatin

10mg/d,p.o,12 weeks.

OTHER

Therapeutic Lifestyle Change

* Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day) * Therapeutic options for enhancing LDL lowering * Weight reduction * Increased physical activity

Sponsors & Collaborators

  • University of British Columbia

    collaborator OTHER

  • State Administration of Traditional Chinese Medicine of the People's Republic of China

    collaborator OTHER_GOV

  • The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

    lead OTHER

Principal Investigators

  • Xiaorong Chang, Prof. · Hunan University of Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-12-31
Completion
2017-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02269046 on ClinicalTrials.gov